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A B S T R A C T
We herein present the first left atrial appendage (LAA) percutaneous closure proce-
dure performed in our Institution with use of the Watchman device in an 82-year old 
woman with atrial fibrillation, unable to continue receiving anticoagulation therapy 
due to bleeding complications. A propos with this case, we discuss the data related to 
this therapeutic approach geared to prevent thromboembolism in patients with atrial 
fibrillation and contraindications to treatment with anticoagulants.
I N T R O D U C T I O N
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its increasing 
incidence has serious socioeconomic consequences, because of its association with 
ischemic stroke.1 Patients with AF have an average 5% annual risk of ischemic stroke 
and a 5-fold higher risk compared to an age-matched population in sinus rhythm.1 The 
percentage of strokes attributable to AF increases steeply from ~1.5% at 50–59 years of 
age to more than 20% at 80–89 years of age.1 Age, previous history of stroke/transient 
ischemic attack (TIA), hypertension, diabetes mellitus, left ventricular dysfunction and 
a large left atrium are factors contributing to increased risk of stroke. 
The most important aspect of treatment of patients with AF is the prevention of 
stroke. Currently, this is best achieved with oral anticoagulation therapy, albeit with 
its inherent bleeding complications.2 Strokes associated with AF have worse outcomes 
than those that occur due to other reasons. Data from the SPINAF registry shows that 
15% of patients with AF suffer from silent cerebral infarcts, detected on computed 
tomography, the effects of which are unknown.3 According to echocardiographic and 
other data,4 the left atrial appendage (LAA) is considered to be the main site of throm-
bus formation and major source of consequent emboli in patients with AF. However, 
other important factors, including systemic atherosclerosis, coagulation disorders 
and increased platelet activation are also implicated in thrombus formation.5 Other 
sources of emboli include the patent foramen ovale, the atrial septum aneurysms and 
the presence of atherosclerotic plaque in the proximal part of the aorta, which can be 
present in more than 50% of cases. From diagnosed strokes, 32% are not considered 
to be cardioembolic.
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Percutaneous closure of the LAA is already available in the 
therapeutic armamentarium of interventional cardiologists, as 
an alternative strategy to long-term use of oral anticoagulants, 
when these are ineffective or contraindicated.6 The occlusion 
of the LAA has been included in the latest guidelines of the 
European Society of Cardiology (ESC) for the management 
of patients with AF (Class IIb, level of evidence B).7 
C A S E  P R E S E N T A T I O N
In October 2013, at the ‘Hippokration’ General Hospital 
of Athens, the first LAA closure procedure was performed 
in an 82-year old woman, through successful implantation of 
a Watchman device. The patient had a history of paroxysmal 
non-valvular AF and arterial hypertension under therapy with 
irbesartan. One year earlier, anticoagulation with dabigatran 
110 mg bid was initiated, which caused significant skin bruis-
ing and an episode of gastrointestinal bleeding. Consequently, 
dabigatran was switched to acenocoumarol. However, bleeding 
complications occurred again, with INR 2.3 causing very large 
skin bruising and ocular bleeding with partial loss of vision. 
The remaining past medical history was significant for trochan-
teric fracture surgery one year earlier, whereby enoxaparin 
was administered for a month without complications, and for 
partial gastrectomy performed 13 years earlier due to stomach 
cancer. No history of diabetes mellitus, smoking, dyslipidemia 
and previous stroke or TIA was reported.
Due to the above history, LAA occlusion was decided as 
an alternative therapeutic option to long-term anticoagulation. 
Transthoracic and transesophageal echocardiography (TEE) 
were performed pre-procedurally to exclude the presence of 
thrombus within the appendage, or atrial septal defect or an-
eurysm, significant valvular disease, or aortic arch atheroma, 
and to assess left ventricular function. The estimated CHA2DS2 
VASc score was 4, with an estimated annual risk of stroke 4% 
and the HAS-BLED score was calculated at 4.
The procedure was performed under general anesthesia 
under fluoroscopic and TEE guidance (Fig. 1). The atrial 
septum puncture system (HeartSpan - Transeptal Needle 
and Stylet Kit) was advanced through the right femoral vein, 
assisted by an 11F-sheath (Fig. 2). Intravenous heparin was 
administered with a target activated clotting time (ACT)> 
250 sec. A 5F pigtail catheter was advanced through the long 
sheath and a LAA angiography was performed (view: RAO 
28° - Cranial 20°) (Fig. 3-1, 3-2). Subsequently, appropriate 
measurements of the «neck» of the LAA were taken (Fig. 
4-1, 4-2). Based on TEE, the diameter of the «neck» of the 
LAA was 18 mm and the presence of thrombus was excluded. 
Accordingly, a 24 mm Watchman device was selected. The 
Watchman device was launched through the dedicated 14F 
introducer and delivery long sheath (Watchman Access Sys-
tem, Boston Scientific) (Fig. 5-8). The device can be partially 
FIgURE 1. The procedure was performed under general anes-
thesia with fluoroscopic and transesophageal echocardiography 
(TEE) guidance.
FIgURE 2. Ultrasound image of the atrial septum puncture.
recaptured and redeployed if the implant location is deemed 
unsatisfactory or recaptured completely if a different sized 
device is determined to be more suitable. After stability 
control was performed, the device was successfully released. 
The device was implanted successfully through the sheath to 
the predetermined position without residual communication 
between the LAA and the left atrium (Fig. 9). Complete oc-
clusion of the LAA was confirmed by color-Doppler TEE 
(Fig. 10). A final angiogram confirmed complete occlusion 
and good circumferential contact of the disk of the device at 
the orifice of the LAA (Fig. 11). There was no pericardial effu-
sion or other significant complication; Figure 12 shows a small 
residual interatrial septal communication. The total duration 
of the procedure was 90 minutes and 200 ml of contrast were 
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employed. After 24 hours, new fluoroscopic imaging confirmed 
the stability and the proper position of the device (Fig. 13). 
D I S C U S S I O N
Atrial fibrillation (AF) has been associated with endothe-
lial dysfunction,8 as documented by a decrease in plasma levels 
of nitrite/nitrate and impaired blood flow, mediated by an 
increase of acetylcholine. Endothelial dysfunction is known 
to increase oxidative stress and the levels of proinflammatory 
agents. Atrial fibrillation is also associated with a systemic 
hypercoagulable state. Platelet function is enhanced with 
increased plasma levels of beta- thromboglobulin and plate-
let factor 4. Systematic markers of the activated coagulation 
cascade, such as the thrombin-antithrombin II complex, D- di-
mers, fibrinogen and fragments 1 and 2 of prothrombin are also 
FIgURE 3-1. A 5F pigtail catheter was advanced through the 
introducer sheath and a LAA angiography was performed. LAA 
= left atrial appendage.
FIgURE 3-2. Ultrasound view of the 5F pigtail catheter into the 
left atrial appendage.
FIgURE 4-1. Angiographic view for the measurement of the 
“neck” of the left atrial appendage.
FIgURE 4-2. Ultrasound view for the measurement of the 
“neck” of the left atrial appendage.
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FIgURE 5. The Watchman device was launched through the 
dedicated 14F delivery catheter.
FIgURE 6. Angiographic view of the Watchman device into the 
left atrial appendage before the release.
FIgURE 7. Ultrasound view of the Watchman device deployed 
into the left atrial appendage.
FIgURE 8. Ultrasound view of the Watchman device deployed 
into the left atrial appendage (LAA), after angiographic con-
trast injection, indicating satisfactory device position within the 
LAA.
the aorta, the left ventricle and cerebral vasculature.5 
The left atrial appendage is an embryonic residual9 of the 
original left atrium and is a long, tubular, trabecular structure 
of 2-4 cm in length, in continuity with the left atrial cavity. Its 
unique anatomy predisposes to in-situ thrombus formation, as 
more than 90% of atrial thrombi in patients with non-valvular 
AF are considered to originate from the LAA.4 Failure of the 
atrium to contract during AF, results in clot formation within 
the LAA.
Warfarin treatment has been established2 as the standard 
of care for the prevention of stroke in patients with AF and 
more than one risk factor for stroke. Compared to placebo 
and antiplatelet agents, warfarin reduced the rate of stroke 
elevated. In summary, patients with AF are characterized by 
a significant atherosclerotic burden and a systemic prothrom-
botic condition, that increase the likelihood of thrombosis and 
embolism from multiple sources except for the LAA, such as 
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FIgURE 9. Angiographic view of the released Watchman device 
without residual communication between the appendage and 
the left atrium.
FIgURE 10. The complete occlusion of the LAA was confirmed 
by color-Doppler TEE. LAA = left atrial appendage; TEE= 
transesophageal echocardiography. 
FIgURE 11. The final angiogram confirmed complete occlusion 
and good circumferential contact of the disk of the device at the 
orifice of the left atrial appendage.
FIgURE 12. Transesophageal echocardiography with color flow 
Doppler indicates flow via a small residual atrial septal defect.
by 64% and 37% respectively. This is a significant therapeu-
tic effect compared with other treatments in cardiovascular 
medicine. Moreover, even with an absolute increase in the risk 
of intracerebral hemorrhage and major bleeding of 0.2 % per 
year over antiplatelet therapy, warfarin still leads to a statisti-
cally significant 26% reduction of total mortality compared 
to placebo. Despite the proven benefit, warfarin treatment is 
administered only to 25%-50% of patients with AF and only 
to 70% of patients who are considered ‘ideal’ candidates for 
warfarin. Furthermore, warfarin therapy may need to be dis-
continued at rates as high as 20% within 2.5 years of follow-up, 
as documented in the FRACTAL study.10 
The main limitation of warfarin is the concern of bleeding 
and this often prevents its use in potentially suitable patients. 
It has been reported that patients are within the therapeutic 
range in only 50% - 68% of the time monitored.11 The rela-
tionship between INR fluctuations and their consequences 
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FIgURE 13. After 24 hours new fluoroscopic imaging confirmed 
the stability and the proper position of the device.
FIgURE 14. The Watchman device consists of a self-expandable mesh with a nitinol frame and polyethylene terephthalate (PET) 
membrane cap; comes in 21, 24, 27, 30, 33 mm diameter sizes; it has 10 active fixation anchors for stability and retention.14
are well documented, with low INR leading to an increased 
risk of stroke and high INR associated with an increased risk 
of bleeding.11 Hence the interest in alternative strategies 
has increased, including the use of devices which poten-
tially occlude the LAA from the rest of the left atrial cavity. 
Such a device is the WATCHMAN device5,12-15 (Fig. 14), 
which is introduced percutaneously through the femoral 
vein, and via transseptal puncture the device is implanted 
into the LAA, under fluoroscopic and transesophageal 
ultrasound guidance.
The Watchman device was evaluated in the PROTECT AF 
study,12-15 a multicenter, randomized noninferioty trial of LAA 
closure with the Watchman device versus standard warfarin 
treatment. Consecutive patients (n=707) with paroxysmal, 
persistent or permanent non-valvular AF and CHADS2 score 
≥1 were randomized in a 2:1 ratio to those who received the 
Watchman device plus short warfarin therapy (45 days) and 
to those who received conventional warfarin treatment. Ac-
cording to the study protocol, patients randomized to the 
device would receive therapeutic heparin during implantation 
(ACT>250 s), followed by warfarin for 45 days after the proce-
dure, aspirin and clopidogrel for 6 months after randomization 
and subsequent long-term monotherapy with aspirin. Exclusion 
criteria included contraindications to warfarin, comorbidities, 
except for AF requiring chronic use of warfarin, presence of 
thrombus in the LAA, patent foramen ovale with presence 
of atrial septum aneurysm and right to left communication, 
mobile atheroma in the aorta, and symptomatic carotid artery 
disease. 
The Watchman device has also been evaluated in the 
CAP registry, which had the same inclusion and exclusion 
criteria as the PROTECT AF study.12 The primary efficacy 
endpoint was the combination of the occurrence of ischemic 
and hemorrhagic stroke, cardiovascular or unexplained death, 
and systemic embolism. The primary safety endpoint consisted 
of life-threatening bleeding, such as intracranial hemorrhage 
and gastrointestinal bleeding requiring transfusion and 
procedure-related complications, such as stroke associated 
with the procedure, pericardial effusion requiring interven-
tion and device embolization, requiring retrieval. During a 
mean follow-up of 18 months, the rates of the primary efficacy 
endpoint of cardiovascular death, stroke or systemic embolism 
were 3.0 events per 100 patient-years in the device group vs 4.9 
in the control group (RR: 0.62 and 95% confidence interval 
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Bayesian 0.35-1.25). Hence, the device did not appear inferior 
to warfarin therapy. The incidence of ischemic stroke and 
systemic embolism was not significantly higher in the device 
than in the control group, but the number of events was small 
and a real difference between the groups cannot be excluded. 
Cardiovascular or death from any cause and hemorrhagic 
stroke was significantly less frequent in the device than in 
the control group. The incidence of any stroke and all-cause 
mortality did not differ significantly between the two groups. 
The stroke event rates were 2.6 events per 100 patient-years 
in the device group versus 3.5 events per 100 patient-years 
in control group (relative risk 0.74 with 95% CI 0.36 – 1.76). 
The incidence of ischemic stroke was 50% higher in the device 
group (3.0% versus 2.0 %), partly due to events that occurred 
early after implantation of the device. The primary safety end-
point5 (composite of major bleeding or complications related 
to the procedure) occurred more frequently in the device than 
in the control group (RR: 1.69 with 95% CI 1.01 to 3.19). Most 
adverse events occurred early in the device group compared 
with the control group. During the periprocedural period in 
the device group, approximately one in 20 patients required 
drainage of pericardial effusion and one in 50 required open 
heart surgery. 
Of the 449 implantation procedures, 408 were successful, 
12.3% of patients experienced serious complications, such as 
pericardial effusion requiring drainage or surgery (5%) and 
acute stroke due to air embolism or thrombus (1.1%). In 4 
patients the device subsequently had to be removed because 
of embolization or sepsis. Of notice, only two thirds of patients 
in the control group remained within the therapeutic range 
of INR, reflecting the difficulties associated with the use of 
warfarin even in a controlled environment of a clinical trial. 
In the CAP registry12 there was a significant reduction in the 
incidence of procedure-related events within 7 days of the 
procedure (3.7% versus 7.7% in PROTECT-AF, p=0.007). 
Accordingly, the rate of serious pericardial effusion within 
the first 7 days of implantation, which represented over 50% 
of primary safety endpoints in PROTECT AF, was lower in 
CAP registry (5.0% vs 2.2%, respectively, p = 0.019). Similarly, 
there was a reduction in the incidence of strokes of the first 
study (PROTECT AF) in the second recording (CAP) (0.9% 
vs 0%; p= 0.039). As with all invasive procedures, there was 
a significant improvement in the safety of Watchman device 
implantation in LAA with the increasing experience of the 
operators.
LAA closure can potentially prevent strokes in AF on the 
long term, but still lacks definitive proof that it is effective 
and safe. Given the extent of atherosclerotic plaques in some 
patients with AF, and the presence of a systemic disorder of 
coagulation and platelet function in most high-risk patients, 
a local approach to the LAA occlusion alone may not be suf-
ficient. Although recent results with percutaneous closure 
device is promising, evidence of efficacy and safety are insuf-
ficient to recommend this approach for each patient, except 
for those in whom long-term warfarin therapy is absolutely 
contraindicated. Further large randomized studies are neces-
sary. But even today, oral anticoagulants remain the standard 
of care for preventing stroke in patients with AF.
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